LEHI, Utah and LOUISVILLE, Ky., Nov. 26, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at two upcoming investor conferences:
Waystar will provide live webcasts of both events on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$36.17 |
Daily Change: | 0.46 1.29 |
Daily Volume: | 1,570,610 |
Market Cap: | US$6.900B |
October 01, 2025 September 10, 2025 September 09, 2025 July 30, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load